Weekly Digest – February 2025 Weekly Digest – February 2025 26 Feb 2025: Pyxis Oncology granted FDA fast track designation for PYX-201 monotherapy in patients with recurrent or metastatic head and neck cancer The FDA has granted Fast Track Designation […]
Weekly Digest – February 2025 Weekly Digest – February 2025 25 Feb 2025: Hansoh Pharma’s HS-20093 receives Breakthrough Therapy Designation from NMPA for Osteosarcoma Hansoh Pharma’s B7-H3-targeted ADC, HS-20093, has been granted Breakthrough Therapy Designated Drug status by China’s NMPA […]
Weekly Digest – February 2025 Weekly Digest – February 2025 24 Feb 2025: Akeso highlights collaboration between its partner Summit Therapeutics and Pfizer to explore Ivonescimab in combination with Pfizer’s ADCs Akeso announced that its partner, Summit Therapeutics, has collaborated […]
Weekly Digest – February 2025 Weekly Digest – February 2025 25 Feb 2025: MEDSIR & Debiopharm announce the first patient dosed in the WIN-B trial exploring the combination of Debio 0123 & Gilead’s Trodelvy in advanced breast cancer Debiopharm and […]
Weekly Digest – February 2025 Weekly Digest – February 2025 27 Feb 2025: First patient dosed in a Phase 3 clinical study of anti-HER2 biparatopic ADC JSKN003 for the treatment of HER2-positive breast cancer Alphamab Oncology and CSPC have initiated […]
Weekly Digest – February 2025 Weekly Digest – February 2025 24 Feb 2025: OS Therapies forms subsidiary OS Drug Conjugates and initiates review of strategic options for its tunable ADC & drug conjugates platforms OS Therapies has launched a subsidiary, […]
